Trials / Completed
CompletedNCT02909751
Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Vejle Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate whether tocotrienol can improve the effect and reduce the side effects of standard chemotherapy before operation for breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epirubicin 90 mg/m2 iv | Max. 3 months |
| DRUG | Cyclophosphamide 600 mg/m2 iv | Max. 3 months |
| DRUG | Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv | Max. 3 months |
| DRUG | Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only) | Max. 3 months. |
| DRUG | Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only) | Max. 3 months |
| DIETARY_SUPPLEMENT | Tocotrienol 300 mg x 3 daily | Max. 6 months |
Timeline
- Start date
- 2016-09-14
- Primary completion
- 2019-01-21
- Completion
- 2019-01-21
- First posted
- 2016-09-21
- Last updated
- 2021-05-20
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT02909751. Inclusion in this directory is not an endorsement.